KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Inventory Average (2016 - 2025)

Historic Inventory Average for Halozyme Therapeutics (HALO) over the last 15 years, with Q3 2025 value amounting to $183.7 million.

  • Halozyme Therapeutics' Inventory Average rose 2634.01% to $183.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.7 million, marking a year-over-year increase of 2634.01%. This contributed to the annual value of $134.7 million for FY2024, which is 1832.79% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Inventory Average is $183.7 million, which was up 2634.01% from $173.2 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Inventory Average high stood at $183.7 million for Q3 2025, and its period low was $50.8 million during Q1 2022.
  • In the last 5 years, Halozyme Therapeutics' Inventory Average had a median value of $120.0 million in 2023 and averaged $112.8 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Inventory Average plummeted by 1462.84% in 2022, and later surged by 10423.53% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Inventory Average stood at $54.9 million in 2021, then surged by 85.1% to $101.7 million in 2022, then grew by 26.12% to $128.3 million in 2023, then grew by 6.53% to $136.6 million in 2024, then surged by 34.41% to $183.7 million in 2025.
  • Its Inventory Average was $183.7 million in Q3 2025, compared to $173.2 million in Q2 2025 and $153.4 million in Q1 2025.